Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)
November 27, 2023 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel)
Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023
November 15, 2023 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023
Autolus Therapeutics announces participation in upcoming conferences
November 06, 2023 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics announces participation in upcoming conferences
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 in Two Oral Presentations and Two Poster Presentations
November 02, 2023 09:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
November 02, 2023 07:11 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus
October 17, 2023 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus
Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
October 11, 2023 08:07 ET
|
Autolus Therapeutics plc
Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
October 11, 2023 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal Blood
September 05, 2023 07:00 ET
|
Autolus Therapeutics plc
Data support utility of AUTO1/22 approach in preventing antigen evasion in pediatric B-ALLComplete responses observed in patients with CD19 negative disease No antigen negative relapse seen in...
Autolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational Progress
August 03, 2023 07:00 ET
|
Autolus Therapeutics plc
Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL), on track for a Biologics License Application (BLA) submission to the US...